Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02301364 · ClinicalTrials.gov registry record · Phase 2
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
A Phase 2 study of Lymphoma and Primary Central Nervous System Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 4
- Study locations
NCT02301364 is a Phase 2 study of Lymphoma and Primary Central Nervous System Lymphoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT02301364, a Phase 2 study of Lymphoma and Primary Central Nervous System Lymphoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to find out what effects, good and/or bad, Buparlisib (also known as BKM120) has on lymphoma and the central nervous system.
Conditions Studied
Interventions
- DRUG Buparlisib (BKM120)
Study Locations (4)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering West Harrison - Harrison
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memoral Sloan Kettering Cancer Center - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-11-20 |
| Est. Completion | 2016-10-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02301364
The ClinicalTrials.gov registry entry for NCT02301364 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (99% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Buparlisib (BKM120) is the first listed.
NCT02301364 reports 4 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02301364 about?
NCT02301364 is a clinical study titled "Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)". The purpose of this study is to find out what effects, good and/or bad, Buparlisib (also known as BKM120) has on lymphoma and the central nervous system.
What is the current status of trial NCT02301364?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2014-11-20. Estimated completion is 2016-10-11.
What conditions does trial NCT02301364 study?
This clinical trial studies the following conditions: Lymphoma, Primary Central Nervous System Lymphoma, Recurrent/Refractory Secondary Central Nervous System Lymphoma.
What interventions are being tested in trial NCT02301364?
The interventions under investigation include: Buparlisib (BKM120) (DRUG).
Who is sponsoring clinical trial NCT02301364?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02301364 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.